Trial Profile
Phase 3 study of TW001 in patients with Amyotrophic Lateral Sclerosis
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 23 Oct 2021
Price :
$35
*
At a glance
- Drugs Edaravone (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Registrational; Therapeutic Use
- 20 Oct 2021 According to a Ferrer media release, Ferrer and Treeway enter into licence agreement. Ferrer has committed to advance Edaravone to the required pivotal phase III trial.
- 02 Dec 2015 New trial record
- 01 Dec 2014 According to a Treeway B.V. media release, TW001 received orphan drug designation from European Medicines Agency (EMA) for the treatment of Amyotrophic Lateral Sclerosis (ALS).